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New battlefi  elds for costimulation
Natalia Martin-Orozco and Chen Dong
The outcome of a naive T cell’s en-
counter with an antigen-carrying den-
dritic cell (DC) in secondary lymphoid 
organs depends on the maturation and 
activation status of the DC, in particu-
lar on the costimulatory molecules ex-
pressed by DCs. There are both   positive 
and negative costimulatory molecules, 
which may individually or collectively 
regulate T cell activation thresholds. If 
the positive signals are strong, T cells 
will be activated and diff  erentiate into 
eff   ector cells. If the negative signals 
dominate, T cells may be deleted or 
  inactivated. The critical positive costi-
mulatory receptors on T cells are the 
immunoglobulin superfamily molecules 
CD28 and ICOS (inducible costimula-
tor), which bind the B7 family ligands 
B7-1/B7-2 and B7h, respectively. The 
fi  rst negative costimulatory receptor on 
T cells to be characterized was cytotoxic 
T lymphocyte antigen (CTLA)-4, which 
also binds to B7-1 and B7-2. Recently 
several novel costimulatory receptors 
have been shown to negatively regulate 
T cell activation, in  cluding the CD28 
family molecules pro    grammed death 
(PD)-1 (1), which binds PD-1 ligand 
(PD-L1; also known as B7-H1) and 
PD-L2 (also known as B7-DC), and B 
and T lymphocyte attenuator (2), which 
binds herpesvirus entry mediator (3). In 
addition, the new B7 family ligands B7-
H3 (4, 5) and B7-H4 (also known as 
B7S1 or B7x) (6–8) have been shown to 
inhibit T cell activation, but their recep-
tors on T cells are not yet known.
The expression of B7-1 and B7-2 is 
restricted to professional antigen-pre-
senting cells. The newer B7 family 
members, however, are widely expressed 
in many diff  erent tissues by both hema-
topoietic and nonhematopoietic cells, 
suggesting that these molecules may reg-
ulate T cells in settings beyond initial 
priming in lymph nodes. For instance, it 
has been shown that PD-L1 is expressed 
in the maternal part of the placenta dur-
ing gestation; blockade of PD-L1 in-
creased the spontaneous abortion rate, 
which indicates that PD-L1 is at the 
front line of fetomaternal tolerance (9).
First new battlefi  eld: preventing 
autoimmune tissue destruction
PD-1 ligands have diff  erent tissue ex-
pression patterns, which suggest that 
they have diff  erent roles in regulating 
immune responses (1). PD-L1 is ex-
pressed by many tissues and various 
cancer types. In mouse hematopoietic 
cells, PD-L1 is expressed on T cells, B 
cells, macrophages, and DCs. In con-
trast, PD-L2 is only expressed on mac-
rophages and DCs. Thus, both PD-L1 
and PD-L2 may regulate T cells in the 
lymph nodes, whereas PD-L1 may have 
additional roles in regulating T cells in 
tissues or tumors.
The role of PD-1 ligands in naive 
T cell activation has been controversial. 
Results provided by several groups 
  using diff   erent experimental systems 
have indicated that under some condi-
tions PD-1 ligands can be activators of 
T cells, whereas in other conditions 
they can be inhibitors (1). In the case of 
type 1 diabetes in nonobese diabetic 
(NOD) mice, blocking PD-L1 using 
antibodies was shown to rapidly precip-
itate the disease, indicating that PD-L1 
inhibits autoreactive T cells (PD-L2 
blockade had no eff  ect) (10).
PD-L1 mRNA is constitutively ex-
pressed in several tissues such as heart, 
skeletal muscle, lung, kidney, and liver. 
The protein is found in macrophage-
derived cells, such as Kupff  er cells in 
liver, macrophages in lung, and histo-
cytes in the paracortical region of tonsil 
(11). The promoter region of PD-L1 
contains several interferon (IFN)-γ–
  responsive elements (12), suggesting that 
PD-L1 protein expression may be in-
duced as a result of a localized immune 
response. Indeed, PD-L1 protein is 
found in multiple human carcinomas 
(lung ovarian, renal, colon, melanoma, 
head and neck, and breast cancer) and 
can be induced in tumor cells lines with 
IFN-γ (11). Also, PD-L1 expression in 
tumors facilitates immune evasion by 
dampening T cell immunity, inducing 
apoptosis of tumor-reactive T lympho-
cytes (11), and conferring resistance to 
cytolysis by tumor-specifi  c CD8 T cells 
(13). Moreover, blocking PD-L1 im-
proves antitumor immunity in several 
experimental tumor models (13).
In this issue, Keir et al. (p. 883) 
  analyzed  PD-L1−/−,  PD-L2−/−, and 
doubly defi  cient mice (14). They found 
that the absence of both molecules in 
the BALB/c strain led to a greater 
  increase in the expression of the cyto-
kines interleukin (IL)-2 and interferon 
(IFN)-γ by T cell receptor transgenic 
T cells activated in vitro compared with 
cells from mice lacking just one of the 
PD-1 ligands. This indicates that PD-
L1 and PD-L2 are negative regulators 
of T cell activation in this setting and 
they may synergistically inhibit T cell 
activation. The authors further analyzed 
the function of PD-1 ligands in auto-
immune diabetes. Double-defi  cient 
(PD-L1/PD-L2−/−) NOD mice, similar 
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to PD-1−/− animals on the same back-
ground (15), developed diabetes by 7 
weeks of age with 100% penetrance in 
males and females. In wild-type NOD 
mice, in contrast, diabetes appeared af-
ter week 20 and occurred predomi-
nantly in females. Furthermore, mice 
defi  cient in PD-L1, but not PD-L2, de-
veloped diabetes with full penetrance in 
males and females by week 10, indicat-
ing that PD-L1 is required for resistance 
to autoimmune attack in the male mice. 
Infi  ltration of cells into the islets (insulitis) 
also occurred earlier in PD-L1/PD-
L2−/− animals than in wild-type NOD 
mice, with more T cells proliferating in 
the pancreatic lymph node, suggesting 
that a negative signal through PD-1 oc-
curs early during T cell priming.
Furthermore, the authors described 
an additional layer of T cell regulation by 
PD-L1. They reported that PD-L1 ex-
pressed on pancreatic islets may prevent 
diabetes by providing a negative costimu-
latory signal to infi  ltrating  autoreactive 
CD4+ T cells (Fig. 1). In these experi-
ments, the authors generated bone mar-
row chimeric mice and found that, 
surprisingly, expression of PD-L1 and 
PD-L2 by antigen-presenting cells, such 
as DCs, was not suffi   cient to prevent ac-
celerated diabetes in PD-L1/PD-L2−/− 
mice.  PD-L1/PD-L2−/− mice that re-
ceived wild-type bone marrow cells 
reached the 100% incidence of diabetes 
only slightly slower than the mice that re-
ceived PD-L1/PD-L2−/− cells. This sug-
gests that PD-L1 expressed by parenchyma 
cells may play a more important role than 
PD-L1 expressed on DCs. In support of 
this idea, the authors found that wild-type 
islets were more protected than PD-L1/
PD-L2−/− islets from autoimmune de-
struction when they were transplanted 
into diabetic mice. Thus, PD-L1 appears 
to have a strong inhibitory infl  uence on 
autoreactive T cells in the islets, possibly 
by preventing cytokine secretion at the 
tissue site. Further research is required to 
detail whether PD-L1 in the islets also 
promotes T cells deletion or anergy, or 
whether it simply stops T cell prolifera-
tion and cytokine expression.
Ansari et al. had shown earlier that 
PD-L1 but not PD-L2 was the main 
  ligand of PD-1 restricting autoimmune 
diabetes in NOD mice (10). In addition, 
Liang et al. had reported that PD-L1 
protein expression is up-regulated in in-
fi  ltrated islet cells from 9-week-old NOD 
mice (16). So it was not surprising to fi  nd 
that PD-L1 is the main factor preventing 
autoimmune attack at the islet level. It is 
possible that islet β cells, similar to tu-
mors, sense IFN-γ produced by early in-
fi  ltrating autoreactive T cells and further 
up-regulate PD-L1 to protect them from 
the autoimmune destruction. However, 
earlier work from another group showed 
that transgenic expression of PD-L1 in 
islet β cells in the C57BL/6 mouse strain 
provoked spontaneous diabetes in some 
mice (17), implying that PD-L1 can pro-
mote autoreactive T cell activation. It is 
not clear why such sharply contrasting 
functions of PD-L1 in islets have been 
found. Genetic background is one possi-
ble explanation. It is also possible that 
the two studies analyzed nonoverlap-
ping   autoimmune reactions, in which 
one is dominated by CD4+ and the 
other by CD8+ T cells.
Based on the existing literature, it is 
tempting to suggest that PD-L1 is an 
  attractive target for the treatment of 
  autoimmune diseases. However, other 
genetic modifi  ers in humans that may in-
fl  uence the function of PD-1 and its li-
gands need to be considered in order to 
predict the outcome of a treatment. 
Polymorphisms in the PD-1 gene are as-
sociated with susceptibility to lupus, ar-
thritis, and type I diabetes, but so far there 
are no reports of polymorphisms in the 
genes encoding PD-1 ligands (18). PD-1 
defi  ciency in diff  erent mouse strains re-
sults in diff   erent autoimmune pheno-
types—cardiomiopathy in BALB/c, 
lupus nephritis in C57BL/6, and acceler-
ated diabetes in NOD—suggesting that 
there is a genetic aspect to the regulation 
of PD-1 function in diff  erent tissues.
Second new battlefi  eld: tumor tolerance
Blocking negative costimulatory mole-
cules to boost antitumor T cell re-
sponses in cancer patients is an attractive 
new strategy in cancer immunotherapy. 
Antibodies that block CTLA-4 on 
T cells have proven eff  ective in treating 
melanoma patients (19). Although the 
precise mechanism and location of 
anti–CTLA-4’s eff   ects are not fully 
  understood, the effi   cacy of these anti-
bodies at least suggests that tumor-spe-
cifi  c T cells can be activated in patients 
bearing tumors.
When tumors escape immune sur-
veillance and progress to become a solid 
cell mass, immune tolerance mecha-
nisms are established in the tumor 
  microenvironment that strongly inhibit 
infi  ltrating T lymphocyte function (20). 
For example, prostaglandin E2 secreted 
by monocytes and tumor-associated 
macrophages (TAMs) inhibits the pro-
liferation of T cells and promotes 
Figure 1.  PD-L1 mediated protection from 
autoimmune attack. Autoreactive T cells re-
cognize islet-derived antigen presented by DCs 
in the pancreatic lymph nodes. After activation 
and expansion, the diabetogenic clones migrate 
to the islets in the pancreas. (A) Islet cells protect 
themselves from the autoimmune attack by 
expressing PD-L1. (B) Absence of PD-L1 in the 
islets cells as described by Keir et al. (14) allows 
the autoreactive T cells to invade and destroy 
the islet cells, initiating the auto  immune process.COMMENTARY
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T helper (Th)2 responses, which down-
regulate the antitumor Th1 response 
(21). Moreover, prostaglandin E2 pro-
motes the secretion of IL-10 by mac-
rophages, DCs, and tumors, which 
maintains the immunosuppressive envi-
ronment in the tumor. Macrophages 
from tumor stroma also produce the 
immunosuppressive cytokine TGF-β, 
which inhibits the antitumor activities 
of infi  ltrating cytotoxic T lymphocytes, 
natural killer cells, neutrophils, and 
macrophages. In addition, transforming 
growth factor-β induces the produc-
tion of IL-10 by the tumor cells and 
down-regulates the expression of the 
activating receptor NKG2D—an im-
portant regulator of antitumor immune 
surveillance—on CD8+ T cells and 
  natural killer cells (21). In this issue, 
Kryczek et al. (p. 871) show that an-
other mechanism of tumor immune 
evasion involves TAMs that suppress 
T cell activation through B7-H4 (22).
B7-H4 is the newest addition to the 
B7 family that has been shown to nega-
tively regulate T cell activation (6–8). 
The expression of B7-H4 in multiple 
nonlymphoid tissues suggests that it 
might mediate tolerance at the tissue 
level. In addition, human breast and 
ovarian cancers have been found to 
  express B7-H4 (23–25). Interestingly, 
Kryczek et al. report the intracellular 
expression of B7-H4 protein in rece-
ntly isolated human ovarian tumor cells 
from ascites fl  uid or tumor mass, and 
from established ovarian tumor cell lines 
(22). In contrast, cell surface expression 
of B7-H4 was found on the majority 
of freshly isolated TAMs from tumor 
ascites and in the ovarian epithelial 
carcinoma cells. This indicates that 
  localization of B7-H4 protein is regu-
lated, albeit by an unknown mechanism. 
The cytokines IL-6 and IL-10 present 
in the ascites were shown to induce 
expression of B7-H4 on normal blood 
monocytes. However, tumor ascites 
had no direct eff  ect on intracellular or 
cell surface expression of B7-H4 in the 
tumor cells. The authors also found 
that the cytokines IL-4 and granulocyte/
mac  rophage colony-stimulating factor 
(GMCSF) suppressed IL-10–induced 
B7-H4 expression. Thus, the down-
regu  lation of B7-H4 may contribute to 
the potent adjuvant eff  ects of GMCSF 
in cancer immunotherapy.
Expression of B7-H4 by TAMs 
  inhibited the in vitro proliferation and 
eff  ector function of CD8+ T cells spe-
cifi  c for the tumor antigen Her-2/neu. 
  Using morpholino antisense oligonu-
cleotides, the authors showed that the 
  immunosuppression was mediated spe-
cifi  cally by B7-H4 and not other immu-
nosuppressive eff   ectors known to be 
expressed by macrophages, such as PD-
L1, arginase, or inducible nitric oxide 
synthase (21). The B7-H4–dependent 
immunosuppresion by macrophages at 
the tumor site was then confi  rmed in a 
mouse ovarian tumor model. Macro-
phages treated with oligonucleotides to 
block B7-H4 expression reduced the 
growth of tumors implanted in lympho-
cyte-defi  cient mice that received T cells 
specifi  c for tumor antigens. In con-
trast, macrophages treated with control 
oligonucleotides did not infl  uence the 
tumor growth. This further indicates 
that B7-H4 is the critical immunosup-
pressive molecule expressed by TAMs.
A possible scenario that might ex-
plain these fi  ndings is that ovarian can-
cer cells secrete IL-6 and IL-10 to 
induce the expression of B7-H4 on in-
fi   ltrating macrophages, which would 
then inhibit the proliferation of and cy-
tokine production by infi  ltrating T cells 
via B7-H4. IL-10 produced by macro-
phages may also suppress T cell function 
directly (Fig. 2). The data presented by 
Kryczek et al. suggests that blockade of 
B7-H4 enhances the activity of tumor-
infi  ltrating T cells, shifting the balance 
of immunity and immune evasion in 
  favor of tumor destruction (22). It re-
mains unclear what type of T cells (for 
example, Th cells, regulatory T cells, or 
cytotoxic T cells) are targeted by the 
suppressive macrophages. Moreover, 
the B7-H4 receptor on T cells is not 
known. It will be important to identify 
this receptor, determine which cells ex-
press it, and investigate its regulation.
These fi  ndings add another level of 
regulation of host responses to tumors by 
macrophages, which are already known 
to promote angiogenesis and tumor in-
vasion of tissues by a crosstalk with tu-
mor cells (26). TAMs found in the 
basement membrane of solid tumors se-
crete matrix metalloproteinases that pro-
mote the escape of the tumor cells to 
surrounding stromal area where the tu-
mor can continue growing. Macrophages 
also secrete epidermal growth factor, 
which promotes chemotaxis of tumor 
cells to blood vessels, allowing them to 
escape into the circulation. In addition, 
carcinoma cells secrete colony stimulator 
factor (CSF)1 to attract circulating mac-
rophages into the tumor. Additionally, in 
hypoxic areas of   tumors, macrophages 
are induced to secrete proangiogneic 
factors, such as vascular endothelial 
growth factor, CXCL8,   angiopoeitin, 
and cyclooxygenase-2, which promote 
the development new vessels to supply 
the tumors with blood (27).
Future considerations
The two papers in this issue have revealed 
crucial roles of negative costim  ulators in 
preventing tissue and tumor attack by 
  infi  ltrating T  cells (14, 22). Enhancing 
Figure 2.  Tumor immune evasion assisted 
by macrophages. Cells of solid tumors, such as 
ovarian cancer described by Kryczek et al. (22), 
secrete IL-10 and IL-6 to induce the expression 
of B7-H4 in infi  ltrating macrophages, which in 
turn inhibit infi  ltrating T cell functions within 
the tumor environment. IL-10 secreted by 
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the function of these molecules may be of 
benefi  t in the treatment of autoimmune 
diseases, whereas inhibition of their func-
tion might be an eff  ective  the  rapeutic 
strategy to boost antitumor immunity.
Tumor immunity and autoimmunity 
are alike to some extent. Tumor reactiv-
ity and autoreactivity exist in our T cell 
receptor repertoire but are restricted by 
many inhibitory mechanisms such as 
peripheral tolerance and the action of 
regulatory T cells. The studies discussed 
in this article, along with others, suggest 
that further checkpoints exist in tissues 
and tumors that are mediated by negative 
costimulatory molecules such as PD-L1 
and B7-H4. These studies also suggest 
that cytokines (pro- or antiinfl  ammatory) 
are crucial regulators of the expression of 
these inhibitory molecules.
A lot still needs to be learned about 
negative costimulation in tissues and tu-
mors and its role in regulating T cell 
activity. For instance, is positive co-
stimulation in tissues or tumors required 
for the function of self- or tumor-
  reactive T cells? And what are the dif-
ferences in the function and regulation 
of the various negative costimulators? 
From our experience in studying co-
stimulation in the context of the regula-
tion of naive T cell activation, we may 
expect to observe combinations of vari-
ous positive and negative costimulatory 
factors that regulate T cell activities in 
tissues and tumors. Thus, it may even-
tually be possible to design eff  ective im-
munotherapies that specifi  cally perturb 
autoimmune responses without imping-
ing on immunity to infection or that 
break tumor tolerance without provok-
ing autoimmune diseases.
We thank our colleagues for discussion.
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